Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXO1 | Q12778 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224539 | 0.92 | NPC1 (0.43) | FOXO1KMT2ANPC1HSP90AA1PKM | |
| SCHEMBL14224552 | 0.92 | SMN1; SMN2 (0.43) | KMT2ANPC1PKMRAB9AMAPT | |
| SCHEMBL14224802 | 0.86 | MAPT (0.41) | NPC1RAB9AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL14224550 | 0.82 | HDAC1 (0.34) | KMT2APKMHPSEMAPTSMN1; SMN2 | |
| SCHEMBL14224553 | 0.82 | AURKA (0.35) | SMN1; SMN2 | |
| SCHEMBL14224524 | 0.81 | MAPT (0.37) | NPC1RAB9AHPSEMAPTSMN1; SMN2 | |
| SCHEMBL14224803 | 0.81 | FPR1 (0.42) | KMT2ANPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL14224801 | 0.79 | CYP11B2 (0.39) | KMT2ANPC1PKMRAB9AHPSE | |
| SCHEMBL14224536 | 0.78 | MCHR1 (0.44) | MAPTSMN1; SMN2ALDH1A1MCHR1 | |
| SCHEMBL14224675 | 0.78 | MAPT (0.43) | KMT2ANPC1PKMRAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | FOXO1 1786/4885KMT2A 3292/4885NPC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.